(Q33711632)

English

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

reproducibility

1 reference

based on heuristic

inferred from title

1

object named as

Hitoshi Tsuda

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Masafumi Kurosumi

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shinobu Umemura

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sohei Yamamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Takayuki Kobayashi

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Robert Yoshiyuki Osamura

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

7 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

534

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

HER2 testing in the UK: consensus from a national consultation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

The Measurement of Observer Agreement for Categorical Data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

21 June 2018

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immuno

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

Measuring nominal scale agreement among many raters

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-534

21 January 2018

HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958945

30 October 2018

Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability of prognostic factors in breast carcinoma determined by core needle biopsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20925963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1186/1471-2407-10-534

Identifiers

10.1186/1471-2407-10-534

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33711632&oldid=2195679331"